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Abstract
Purpose Non-alcoholic fatty liver disease (NAFLD) is a
hallmark of the metabolic syndrome and has been shown to
be an independent predictor of cardiovascular mortality.
Although glucocorticoids and growth hormone are known
to be implicated in its pathophysiology, it has only rarely
been investigated in the context of patients with pituitary
insufficiency or former cortisol excess.
Methods Case–control study in patients with biochemi-
cally controlled Cushing’s disease (CD; N = 33) and non-
functioning pituitary adenomas (NFPA; N = 79). NAFLD
was estimated by calculating the fatty liver index (FLI)
including BMI, waist circumference, GGT and triglyceride
levels.
Results Although there was no difference in FLI between
patients with NFPA and CD, we identified average daily
hydrocortisone (HC) intake in those with adrenal insuffi-
ciency to be an independent predictor of FLI (b = 1.124;
p = 0.017), even after adjusting for BMI and waist cir-
cumference. In line, those with a FLI[ 60 were also tak-
ing in average significantly more HC per day than those
with a score \60 (21.05 mg ± 5.9 vs. 17.9 mg ± 4.4;
p = 0.01). FLI was also the best independent predictor for
HbA1c and fasting glucose levels (both p = 0.001).
Growth hormone deficiency and replacement therapy were
not associated with FLI in either group.
Conclusions While HC dosage affects FLI as an estimate
of NFLD in patients with CD and NFPA, the benefit of GH
replacement still needs to be determined. In contrast to
reports in CD patients with active disease, NAFLD in those
with biochemical control was not different from NFPA
patients.
Keywords Adrenal insufficiency  Cushing’s disease 
Growth hormone  Fatty liver  Cortisol
Introduction
Non-alcoholic fatty liver disease (NAFLD) is the most
common liver disease in western populations and it is
closely linked to the development of the metabolic syn-
drome [1]. The term encompasses simple steatosis of the
liver as well as non-alcoholic steatohepatitis (NASH).
NASH in turn can ultimately result in liver fibrosis and
cirrhosis and increases also the risk for hepatocellular
carcinoma [2]. Beyond its contribution to metabolic dis-
turbances, it is also an independent predictor of cardio-
vascular mortality [3].
Patients with pituitary adenomas in general and those
with Cushing’s disease (CD) in particular have an
increased cardiovascular risk. In case of CD this is even
true for those who have achieved biochemical control [4].
But also patients with non-functioning pituitary adenomas
(NFPA), in particular those with impairment of pituitary
function, have an increased risk to die from cardiovascular
diseases [5]. In particular growth hormone deficiency and
adrenal insufficiency may explain for the increase standard
mortality ratio in these patients [6]. Pituitary insufficiencies
are also common in CD patients [7], therefore potentially
contributing in addition to the detrimental effects of long-
lasting glucocorticoid (CG) excess to metabolic distur-
bances and cardiovascular mortality [8, 9]. The role of
pituitary insufficiency on cardiovascular parameters in
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Cushing’s disease is only poorly understood and provided
controversial results so far [8–11].
NAFLD has only rarely been investigated in the context
of pituitary adenomas [12–14], though it represents and
interesting candidate to explain for metabolic disturbances
and cardiovascular mortality. It is of special interest in this
particular patient population as the involvement of GC as
well as growth hormone (GH) is suggested to play a fun-
damental role in the development of NAFLD [15, 16].
In line, in a study with CD patients with active disease,
the estimated prevalence of NAFLD by CT measurements
was 20 % and closely related to visceral adiposity [12].
Vice versa, in the general population, increased exposure to
GCs is associated with NAFLD [16]. These findings
underline the critical role of hepatic exposure to GCs for
the development of NAFLD.
The role of the GH/insulin-like growth factor-1(IGF-1)
system in this context is less clear. Both GH and IGF-1 are
however believed to be important in the regulation of
hepatic lipid metabolism [17]. Growth hormone deficiency
(GHD) appears to be associated with increased hepatic
lipid content [14], however interventional studies have
yielded controversial results [13, 14].
Although currently the diagnosis of NAFLD requires a
liver biopsy, non-invasive procedures have been developed
in the past that show adequate concordance with histo-
logical results. This includes the fatty-liver-index (FLI)
[18] which has been demonstrated to be a useful tool to
predict the presence of NAFLD as it shows high accor-
dance with imaging [19] as well as histological criteria for
NAFLD [20]. The index has been shown to be a useful
predictor of arteriosclerosis development and all-cause
mortality, independent of established classical risk factors
in particular in those patients with a score C60 [21].
In the present study we therefore investigated the effects
of long-lasting former cortisol excess in CD on FLI as a
marker of NAFLD in comparison to patients with NFPA, to
disentangle the different effects of past cortisol excess,
present adrenal insufficiency and GHD on NAFLD. We
also investigated if FLI would be a good predictor in this
special population for disturbances in glucose metabolism
and further classical cardiometabolic risk factors.
Methods
Suitable patients were selected from a patient cohort of the
department of Clinical Neuroendocrinology of the Max
Planck Institute of Psychiatry in Munich, Germany who
had been included in the Network of Excellence for Neu-
roendocrine Tumors Munich (NeoExNET), a registry and
biobank alliance of several regional academic institutions.
Data necessary for the calculation of the FLI had not been
systematically assessed before 2012, so only patients that
had visited our department between the years 2012–2014
were included in the present analysis. We only included
patients with CD who were biochemically cured for at least
12 month prior to the analysis (N = 33). Five CD patients
were receiving CD-specific medications at the time of
study inclusion (one cabergolin, three azol-derivates and
one pasireotide).
We further included patients with NFPA (N = 79).
Patients were excluded if GHD had not been documented
by appropriate stimulation tests [22]. We also only inclu-
ded patients who had been diagnosed with GHD for at least
1 year prior to the investigation. To compare for the sus-
tained effects of GH-substitution, we also only included
those in the GH-treated group who had at least been treated
with GH for 12 months prior to the study inclusion.
Adrenal insufficiency had to be documented by adequate
stimulation tests [23]. Evaluation of further pituitary
function, respectively adequateness of treatment based on
basal measurements of thyroid-stimulating hormone
(TSH), free thyroxine, free triiodothyronine, luteinizing
hormone (LH), follicle-stimulating hormone (FSH), and
total testosterone (in men) or oestradiol (in women). Fur-
ther parameters were assessed after an overnight fast
between 8 and 11:30 a.m. using routine clinical methods at
the local laboratory. IGF-1 and GH were measured on the
IMMULITE 2000 analyzer (Siemens, Los Angeles, CA).
In women in the fertile age range, secondary hypogo-
nadism was defined as low LH/FSH in women with sec-
ondary amenorrhea for at least 1 year. In postmenopausal
women, secondary hypogonadism was documented when
gonadotropin levels were inappropriately low for the
postmenopausal age. In men, secondary hypogonadism was
defined as a low testosterone level with an inappropriate
low LH/FSH and secondary hypothyroidism as low free T4
(FT4) with an inappropriately low serum TSH. Patients
with adrenal insufficiency were treated with conventional
hydrocortisone usually divided into 2–3 doses per day.
Secondary hypothyroidism was treated with levothyroxine.
LH/FSH deficiency was treated with testosterone in men
(gel or intramuscular injections) and with estrogen/pro-
gesterone replacement in women or in case of past hys-
terectomy with estradiol only. Most women were receiving
transdermal estradiol preparations.
Patients were also excluded if average alcohol intake
was[30 g/day for men and[20 g for women or if they
had known cirrhosis, hepatitis B or C. Height and weight
were measured to the nearest 0.5 cm and 0.1 kg, respec-
tively. Waist circumference was measured to the nearest
0.5 cm. History of medication intake and comorbidities
was retrieved from the patient files and by interview. FLI
was calculated according to an equation including BMI,
waist circumference, GGT and triglyceride levels [18]. All
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patients gave written informed consent and the study was
approved by the ethical review board of the Ludwig
Maximilian University of Munich.
Statistical analysis
Statistical analysis was conducted using SPSS 21.0 for
Windows software (SPSS Inc). Quantitative data are
expressed as mean ± standard deviation (SD) or standard
error (SE), and categorical data are expressed as percent-
ages. Differences between groups were performed using
v2-tests. Normal distribution of variables was tested by
Kolmogorov–Smirnov-Test and skewed variables were
log-transformed for further testing procedures. Differences
between CD and NFPA patients were evaluated with an
analysis of covariance (ANCOVA) controlling for age and
gender which was different between the groups. Relations
between the outcome variables and continuous variables
were evaluated by univariate Pearson’s correlation coeffi-
cients or Spearman as appropriate. Multivariate linear
regression models were used to investigate the relationship
between depended and independent variables, including
potential influential factors. Logistic regression analysis
was used to test the independence of dichotomous outcome
variables with their significant correlates in univariate
models. Statistical tests were two-sided, and significance
was set at a value of p\ 0.05.
Results
General characteristics
In accordance with the general epidemiological character-
istics of these two pituitary adenoma entities, significantly
more patients with CD were women than patients with
NFPA and they were also significantly younger
(50.3 years ± 13.4 vs. 61.6 years ± 14.5; p = 0.037).
Fewer CD patients had a macroadenoma at the time of
diagnosis (p[ 0.001) but radiotherapy was more fre-
quently applied (p = 0.005). Adjusted mean systolic and
diastolic blood pressure was not significantly different
between NFPA and CD patients and same was true for
those who had already been diagnosed and pretreated with
antihypertensive drugs. Adjusted weight, BMI, and waist
circumference did not differ between the groups. There was
also no significant difference in the rate of patients with
pre-diagnosed and pre-treated type 2-diabetes, intake of
anti-hyperlipidemic drugs and also not for adjusted fasting
glucose, HbA1c, total cholesterol, HDL, LDL, ALAT,
ASAT, AP, GGT fasting triglyceride levels or IGF-1.
There was no significant difference in the total rate of
pituitary insufficiency or total number of affected pituitary
axes, but secondary hypogonadism (p = 0.007) and GHD
(p = 0.015) was more common in NFPA patients than in
those with CD. There was only a trend for more secondary
adrenal insufficiencies in NFPA patients (p = 0.072) and
as five patients had been bilaterally adrenalectomized in the
course of CD, there was no significant difference with
regard to the total rate of adrenal insufficiencies between
the both groups. Average daily HC intake did not signifi-
cantly differ between the groups. There was also no sig-
nificant difference in overall untreated hypogonadism
[defined as primary (=menopause) ? secondary] and
untreated GHD. FLI in NFPA patients in comparison to CD
patients did not differ and same was true for the proportion
of patient with an FLI above or below 60 (Table 1).
FLI as a measure of NAFLD
In the entire study population FLI correlated with female
sex (r = -0.313; p = 0.001), Hb1Ac (r = 0.328;
p = 0.001), fasting glucose (r = 0.404; p\ 0.001), HDL
(r = -0.425; p\ 0.001), BMI (r = 0.852; p\ 0.001),
GGT (r = 0.499; p[ 0.001), triglycerides (r = 0.456;
p\ 0.001), systolic (r = 0.332; p\ 0.001) and diastolic
BP (r = 0.415; p\ 0.001), ASAT (r = 0.432; p[ 0.001)
and ALAT (r = 0.357; p\ 0.001) but not with the ASAT/
ALAT-ratio. There was no significant difference in FLI
scores between patients with and without overt hypogo-
nadism. Same was true for those with untreated GHD in
comparison to those without GHD or those that were on
adequate replacement therapy. There was also no signifi-
cant correlation with IGF-1 levels (p = 0.869) in univari-
ate analysis. FLI did not differ between patients with and
without adrenal insufficiency but there was a trend for a
positive correlation of average daily hydrocortisone intake
(r = 0.253, p = 0.086).
To assess independent predictors of FLI, a multivariate
regression model using backward stepwise removal was
used, entering FLI as a dependent variable and age, sex,
diagnosis (CD vs. NFPA), untreated hypogonadism (pri-
mary ? secondary), adrenal insufficiency, average daily
intake of hydrocortisone replacement, untreated GHD,
IGF-1 and hypothyroidism.
In this model, the only independent predictors were sex
(b = -22.535; p = 0.016) and average daily hydrocorti-
sone intake (b = 1.804, p = 0.042). Even when BMI and
waist circumference, which are part of the FLI calculation,
were included in the model, average daily hydrocortisone
intake remained an independent predictor of FLI scores
(b = 1.124; p = 0.017; Table 2).
In line, those with a FLI[ 60 were also taking in
average a significantly higher daily HC-dosage than those
with a score \ 60 (21.05 mg ± 5.9 vs. 17.9 mg ± 4.4;
p = 0.01; Fig. 1). This finding was independent of age, sex
Pituitary (2016) 19:461–471 463
123
Table 1 General characteristics
Cushing’s disease NFPA p
N % N %
General characteristics
Male 1 3 43 54.4 <0.001
Female 32 97 36 45.6
Mean SD Mean SD p
Age (years) 50.3 13.4 61.6 14.5 0.04
N % N % p
Tumorsize
Macroadenoma 9 27.3 78 98.7 <0.001
Microadenoma 23 69.7 1 1.3
NA 1 3.0 0 0.0
Treatment
Surgery 33 100 72 91.1 0.712
Radiotherapy 13 39.4 12 15.2 0.005
Mean SE Mean SE p
Anthropometry
Weight (kg) 75 3.3 78 2.8 0.535
BMI (kg/m2) 26.6 1 27.8 0.6 0.317
Waist (cm) 94.2 3.1 94 2 0.952
Systolic blood pressure (mmHg) 128.8 3.1 136.9 1.8 0.370
Diastolic blood pressure
(mmHg)
85.2 1.9 85.2 1.1 0.994
N % N % p
Drug intake
Anti-hypertensive treatment
No 19 57.6 19 57.6 0.094
Yes 14 42.4 14 42.4
Anti-hyperglycemic treatment
No 29 87.9 68 86.1 0.798
Yes 4 12.1 11 13.9
Dyslipidemia treatment
No 28 84.8 59 74.7 0.239
Yes 5 15.2 20 25.3
Mean SE Mean SE p
Laboratory
Fasting glucose (mg/dl) 87.3 2.8 84.1 1.7 0.367
Hba1c (%) 5.5 0.1 5.3 0 0.113
Total cholesterol (mg/dl) 212.3 8.2 216.4 5 0.690
HDL (mg/dl) 63.6 3.8 59.5 2.2 0.389
LDL (mg/dl) 136.7 7.2 140.1 4.3 0.708
Triglycerides (mg/dl) 145.3 15.9 141.9 10.1 0.866
Gamma-GT (U/l) 32.8 5.7 32.8 5.7 0.801
ALAT(U/l) 23.0 2.5 26.2 1.5 0.303
ASAT (U/l) 22.4 1.7 26.6 1 0.450
Table 1 continued
Mean SE Mean SE p
AP (U/l) 64.5 4.2 69.3 2.6 0.359
N % N % p
FLI
Mean FLI 47.6 6 49.1 3.6 0.846
Mean SE Mean SE p
FLI\ 60 23 69.7 26 32.9 0.208
FLI[ 60 10 30.3 16 20.3
IGF1 (ng/dl) 118.7 14.3 141 7.8 0.201
Pituitary function
Pituitary insufficiency
No 10 30.3 18 22.8 0.402
Yes 23 69.7 61 77.2
Number of pituitary deficiencies
0 8 24.2 15 19 0.07
1 9 27.3 11 13.9
2 5 15.2 8 10.1
3 7 21.2 18 22.8
4 3 12.1 27 34.2
Secondary hypogonadism
No 20 60.6 26 32.9 0.01
Yes 13 39.4 53 67.1
Menopause 6 18.2 9 11.4 0.724
Total sex steroid deficiency
No 25 75.8 52 65.8 0.301
Yes 8 24.2 26 32.9
Secondary adrenal insufficiency
No 24 72.7 43 54.4 0.07
Yes 9 27.3 36 45.6
Total adrenal insufficiency*
No 19 57.6 43 54.4 0.072
Yes 14 42.4 36 45.6
Mean SE Mean SE p
Average daily hydrocortisone
intake (mg; range 10–30 mg)
20.4 3.3 18.7 5.7 0.324
N % N % p
Secondary hypothyroidism
No 15 45.5 47 59.5 0.173
Yes 18 54.5 32 40.5
GHD
No 19 57.6 26 32.9 0.02
Yes 14 42.4 53 67.1
Treated 7 21.2 29 36.7 0.109
Untreated 7 21.2 24 30.4
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and pituitary function (Table 3), but did however not sur-
vive if BMI and waist circumference were included in the
model (data not shown).
Predictors for cardiovascular risk factors
We determined which factors might predict differences in
other cardio-metabolic variables such as total cholesterol
levels, HDL, LDL, systolic and diastolic BP, fasting glu-
cose and HbA1c levels in a stepwise linear regression
analysis (Table 4). We performed the analysis once for the
whole study population and once only for those who were
not already receiving medical treatment for arterial
hypertension, dyslipidemia or type 2 diabetes, respectively.
Every regression model included age, sex, diagnosis
(CD vs. NFPA), untreated hypogonadism (primary ? sec-
ondary), average dosage of hydrocortisone replacement,
untreated GH deficiency, IGF-1 and FLI scores as inde-
pendent variables.
FLI (p = 0.032) was the best single predictor for HDL-
cholesterol levels. If those were excluded from the analysis
that had already received anti-hyperlipidemic treatment,
only FLI (p = 0.013) and GHD remained significant
(p = 0.037). Age was the only independent predictor for
systolic BP (p\ 0.001), while age (p = 0.001) and sex
(p = 0.012) were predictive for systolic BP in those who
did not already receive antihypertensive medication.
Female sex was the only independent negative predictor of
diastolic BP and remained significant after excluding those
with anti-hypertensive treatment (p = 0.001). HbA1c was
independently predicted by FLI (p = 0.001), age
(p = 0.006) and male sex (p = 0.031). FLI remained the
only significant predictor if those with anti-hyperglycemic
treatment were excluded from the analysis (p = 0.001).
FLI was also the only independent predictor for fasting
glucose levels for those with (p = 0.001) and without anti-
diabetic treatment (p = 0.002; Table 4).
If FLI was substituted by the separate variables used for
its equitation (BMI, waist circumference, triglycerides and
GGT), GGT was the best determinant for HbA1c levels in
the whole study cohort (p = 0.016) and after excluding
Table 1 continued
N % N % p
Overt GHD
No 26 78.8 55 69.6 0.323
Yes 7 21.2 29 36.7
Diabetes insipidus
No 31 93.9 69 87.3 0.303
Yes 2 6.1 10 12.7
p-value (bold if significant)
GHD Growth hormone deficiency, FLI fatty liver index, SE standard
error, SD standard deviation, NA not available
* Including five patients primary adrenal insufficiency due to
adrenalectomy
Table 2 Predictors of the fatty
liver index
Model b SE p value Confidence interval (CI; 95.0 %)
Lowest Highest
Model 1*
Female sex -22.535 8.971 0.016 -39.298 -2.006
HC dosage 1.804 0.859 0.042 0.072 3.536
Model 2**
HC dosage 1.124 0.451 0.017 0.212 2.036
BMI 4.087 0.526 \ 0.001 3.023 5.151
Waist 0.296 0.132 0.031 0.028 0.563
b, Partial regression coefficient; HC, hydrocortisone; SE, standard error of partial regression coefficient
* Included age, sex, diagnosis, untreated GHD, adrenal insufficiency, untreated hypogonadism, secondary
hypothyroidism
** ? BMI ? Waist circumference
Fig. 1 Average daily hydrocortisone intake and FLI[ 60
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those with pretreated diabetes mellitus type 2 (p = 0.012).
GGT was also the best predictor for fasting glucose levels
(p\ 0.001; Table 5).
Discussion
In the present study we could show that HC dosage was an
independent predictor of FLI as a marker of NAFLD. This
association also remained significant after accounting for
waist circumference and BMI. HC intake was also signif-
icantly higher in those with an FLI score[60 which has
been shown to have a high predictive value for NAFLD in
histological analysis [24]. This indicates that an increased
hepatic exposure with hydrocortisone does not only impact
hepatic lipid accumulation via an increase in visceral adi-
posity, which is a well-established consequence of hyper-
cortisolism [25] and may even persist after achievement of
normocortisolism [10], but also by direct effects. The
regression analysis indicates that every mg of HC results in
average in an independent increase of 1.1 units in the FLI.
Though this at first glance seems to be only a moderate
increase, it has also to be kept in mind that it has been
shown in the general population that an increase of the FLI
by only one unit may result in an increased chance of
developing NAFLD by 5.8 %. It is known that GC treat-
ment may result in liver fat accumulation [26], however,
Table 3 Predictors for an
FLI[ 60
Model with FLI (used as a dichotomic variable; FLI C 60 and FLI\ 60)*
Model b SE p value Confidence interval (CI; 95.0 %)
Sex (male) 2.758 0.845 0.027 0.013 00.768
HC dosage 0.201 0.082 0.02 1.041 10.587
b, Partial regression coefficient; SE, standard error of partial regression coefficient; HC, hydrocortisone
* Including age, sex, diagnosis, hypogonadism, secondary hypothyroidism, adrenal insufficiency, untreated
GHD
Table 4 Predictors of cardiovascular risk factors
Dependent variable* All patients Not pretreated**
Independent variable b SE p value Independent variable b SE p value
HDL FLI -0.262 0.118 0.032 FLI -0.356 0.134 0.013
GHD 18.567 8.435 0.037
Systolic blood pressure (mmHg) Age 0.851 0.180 \0.001 Age 0.426 0.152 0.001
Sex -13.622 4.488 0.012
Diastolic blood pressure (mmHg) Sex -10.184 2.723 0.001 Sex -7.852 2.731 0.010
HbA1c (%) FLI 0.008 0.002 0.001 FLI 0.235 0.064 0.001
Age 0.014 0.005 0.006
Sex 0.348 0.156 0.031
Fasting glucose (mg/dl) FLI 0.230 0.068 0.002 FLI 0.235 0.064 0.001
FLI Fatty liver index
* The predictive variables were age, sex, diagnosis, FLI, hypogonadism, HC dosage and untreated GHD and IGF-1
** Patients excluded taking anti-hyperglycemic drugs (for HbA1c, fasting glucose), antihypertensive medication (for systolic, diastolic BP), anti-
hyperlipidemic drugs (for total cholesterol, HDL, LDL), respectively
Table 5 Individual analysis of the components of the fatty liver
index
b SE p value
Model for Hba1c
Model 1*
GGT 0.400 0.155 0.016
Model 2**
GGT 0.342 0.124 0.012
Model for fasting glucose
Model 1*
GGT 18.988 4.297 \0.001
Model 2**
GGT 18.833 3.237 \0.001
The predictive variables were age, sex, diagnosis, overt hypogo-
nadism, HC dosage and untreated GHD, triglycerides, BMI, GGT,
waist circumference
* All patients
** Only patients without anti-diabetic drugs
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this has rather been reported in the context the adminis-
tration of supraphysiological dosage due to its anti-in-
flammatory effect in inflammatory diseases [27]. Although
there is also evidence for general hypothalamo-pituitary-
adrenal (HPA) overactivity in NAFLD patients [28], data
supporting a more tissue specific role of GCs in the
pathogenesis of NAFLD are even more compelling.
These data show that direct cortisol exposure to liver is a
key mediator of liver fat metabolism and NAFLD devel-
opment [26]. The glucocorticoid receptor (GR) is a critical
regulator of liver glucose and lipid homeostasis [29],
mediating effects on hepatic lipid metabolism by directly
promoting liver fat accumulation via an increase in
lipoproteins secretion and up-regulation of enzymes
involved in fatty acid synthesis [30] and inhibition in liver-
specific fatty acid oxidation [31]. In line, liver-specific
knockdown of the GR expression ameliorates steatosis
severity [32].
A critical role seems to be played by the local meta-
bolism of glucocorticoids, in particular conversion of cor-
tisone to cortisol by the 11b-hydroxysteroid dehydrogenase
type 1 (11b-HSD1)-enzyme that is primarily found in
visceral adipose and liver tissue [33]. Hepatic [34] as well
as visceral 11b-HSD1 [35] have both been shown to play a
significant role in the etiology of the metabolic syndrome.
This enzyme is in particular overexpressed in visceral fat of
obese subjects resulting in cortisol-overexposure of the
liver by the splanchnic venous system [36]. This is of
certain importance as already in metabolically healthy
individuals, splanchnic 11b-HSD1 reactivation of cortisone
alone is expected to account for approximately one fourth
of circulating cortisol levels [33].
Correspondingly, adipose tissue specific knock-out of
11b-HSD1 in animal models protects from the develop-
ment of a metabolic syndrome-like phenotype despite
systemic corticosteroid excess [35]. In turn, mice overex-
pressing 11b-HSD1 in the fat tissue show unaltered sys-
temic GC levels while GC levels are increased in portal
vein and as a consequence, these mice are developing
impaired hepatic lipid clearance and steatosis [34]. On the
one hand selective overexpression of 11b-HSD1 results in
the development of all features of the metabolic syndrome
expect obesity [34], on the other hand, selective knock-out
of hepatic 11b-HSD1 is not sufficient to prevent features of
the MS and steatosis, when visceral 11b-HSD1 is still
active and animals are exposed to high doses of GC.
These findings underline the critical role of hepatic
exposure to GCs for the development of NAFLD and the
metabolic syndrome and have promoted the development
of selective inhibitors of 11b-HSD1 [37–40].
Again, while the effects of liver specific 11b-HSD1
inhibition on metabolic parameters have been less con-
vincing [39], the use of an 11b-HSD1 inhibition that targets
both, adipose and liver 11b-HSD1 has shown beneficial
results in type 2 diabetics in addition to metformin therapy
in terms of significant improvements in glycemic control
and dyslipidemia [40]. The importance of local and in
particular visceral glucocorticoid activation is further
underscored by the fact that patients who have been treated
with these drugs show significant improvement in meta-
bolic parameters despite a compensatory increase in ACTH
and subsequently unaltered systemic cortisol levels. In
addition, it was further demonstrated that the improvement
in triglyceride levels and hemoglobin A1c was even more
promising in those with a higher BMI though there was no
difference in baseline metabolic parameters in this regard,
potentially due to the higher 11b-HSD1 expression as a
result of increased visceral adipose tissue in these subjects.
All these findings highlight the importance of hepatic
GC exposure via the portal venous system and coming
back to the findings of our study, it has to be kept in mind
that in contrast to individuals without adrenal insufficiency,
where cortisol is directly secreted from the adrenals into
the systemic circulation, oral intake of HC as hormone
replacement therapy results in a higher liver exposure as it
will first enter the portal venous system and therefore result
in a relatively increased liver exposure.
In keeping, patients with secondary adrenal insuffi-
ciency have an increased overall mortality in particular if
they take more than 20 mg per day [41] and also show an
unfavorable cardiometabolic risk profile. In contrast, our
data do not indicate that preceding hypercortisolism as in
cured CD has a sustained impact on the development of
NAFLD, making other factors more likely to contribute to
the poor cardiometabolic outcome reported in the literature
such as persisting visceral obesity [10].
Adams and colleagues demonstrated in a longitudinal
study in a small subset of patients with hypopituitarism that
NAFLD development may finally resulting in NASH,
fibrosis, cirrhosis and hepatocellular carcinoma, even
demanding liver transplantation due to liver failure [42].
However, a large proportion of this small subgroup
investigated, was suffering from hypothalamic obesity,
potentially differing in terms of NAFLD pathophysiology
in comparison to NFPA patients. According to the authors,
almost all patients were on HC replacement therapy, but
they do not report on dosage.
In contrast to the role of HC-, GHD, respectively GHD
replacement therapy did not seem to have a significant
influence on FLI as a marker of NAFLD in our study
cohort, neither in CD nor in NFPA patients.
Nishizawa and colleagues [14] reported on a high
prevalence of NAFLD of up to 70 % in GHD patients and
also a high prevalence of NASH. They also documented a
significant improvement in terms of liver histology and
liver enzymes in a subgroup of patients receiving GH. The
Pituitary (2016) 19:461–471 467
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high prevalence of NAFLD and NASH may be explained
by a high rate of patients with craniopharyngeoma inclu-
ded, potentially suffering from hypothalamic damage.
Though controls were matched for BMI, these patients may
represent a distinct entity which is not directly comparable
with NFPA patients. In this patient cohort, most patients
were also suffering from adrenal insufficiency but the
authors do not report on replacement regimens. In contrast
Garnder et al. [13] who estimated NAFLD by means of
magnetic resonance spectroscopy did not find an increased
prevalence of NAFLD in comparison to matched controls.
In this cohort only a minority of patients was suffering
from adrenal insufficiency. We can only speculate on the
discrepant findings in these studies but etiology of GHD
and extent of accompanying pituitary insufficiencies and
subsequent replacement regimens may play a role in this
context. It has to be kept in mind that there is a close
interaction between the different hormonal axes. GH for
example is known to suppress 11b-HSD1 activity and
therefore reducing cortisol exposure.
FLI in our cohort was an independent predictor for
conventional cardiovascular risk factors such as HbA1c,
fasting glucose and HDL cholesterol. These findings are in
accordance with the literature [24]. HbA1c and fasting
glucose were best predicted by GGT-levels if analysis of
the four factors contributing to its calculation were inves-
tigated separately. This finding is of interest as GGT levels
have also been suggested to be predictive for mortality also
independent of the presence of NAFLD [41].
Apart from the obvious that HC replacement dosage in
patients with adrenal insufficiency should be as high as
necessary but as low as possible, the clinical implications
of our findings might include to further investigate the
effects of different HC-formulations and application routes
such as modified-release HC and HC via continuous sub-
cutaneous infusion (CSI) on NAFLD development. Modi-
fied-release HC has shown beneficial effects with regard to
metabolic outcome [43–45], although it is still not com-
pletely clear if this is solely due to a reduced overall
bioavailability or due to the more physiological HC
release. It has been shown that patients who had switched
from conventional to a dual-release regimen may benefit in
terms of cardiometabolic parameters without negative
effects on quality of life [43]. Studies comparing conven-
tional HC to extended-release HC showed in particular
significantly lower levels of triglycerides and BMI [43, 44],
both being part of the FLI calculation while others have
shown a reduction in waist circumference but not on
triglycerides [45].
On the other hand if you follow our argumentation that
the direct hepatic HC exposure via the portal circulation
may have more detrimental effects with regard to NAFLD
development, the administration of HC by CSI should
result in benefits with regard to liver steatosis. The so far
available pilot studies on HC administration via CSI did
not investigate the effects on NAFLD, but showed no
benefits with regard to glucose metabolism that is at least
pathophysiologically closely related to liver steatosis as
also being shown in our study by the FLI and GGT being
best predictor for fasting glucose and HbA1c levels. The
interpretation of the results of these studies is however
hampered by the fact that in one study CSI resulted in a
significant increased overall HC exposure in comparison to
the oral dosage potentially counteracting any beneficial
effects exerted by the different route of application and in
the other study area under the curve (AUC) for cortisol
exposure was only determined during the euglycaemic-
hyperinsulinaemic clamp test [46]. It remains therefore
speculative if a same-dose exposure to HC given par-
enterally would be better for liver and metabolic health
than oral application.
There are some limitations that have to be taken into
consideration for the interpretation of our results. The
major limitation refers to the use of an index for deter-
mining NAFLD. Whilst non-invasive assessments of
NAFLD as the FLI are able to provide accurate measure-
ments of increased liver fat, it cannot replace staging of
disease by liver biopsy as they have lower accuracy in
quantifying steatosis. However, the index has been proven
highly accurate in detecting a fatty liver [18] and most
studies in western populations have shown that a FLI\ 30
has an accuracy for excluding NAFLD between 80 and
87 % while a cut off of[60 has a specificity of 80 % for
detecting NAFLD, though cut-off points may be different
[20] in other ethnic populations [47, 48]. The FLI has
initially been developed in a large epidemiological study
from the general population and was tested against the
diagnosis of a fatty liver by a single-operator ultrasonog-
raphy (US) according to four stringent US-criteria [49] that
in turn had shown to diagnose NAFLD defined by a his-
tological confirmed fat content of[30 % with a sensitivity
of 83 % and specificity of 100 % [18]. US has shown
comparable rates of sensitivity in comparison to other
advance imaging techniques such as 1H-MRS, although the
specificity may be lower [50]. The FLI has been shown to
perform equally good in men and women [47, 48], though
some authors did find different cut-off points depending on
sex [48].
Indirect measures of hepatic steatosis by indexes such as
the FLI but also by imaging techniques fail at making the
important distinction between NAFLD and NASH [20, 51].
However, due to the associated high costs, sampling error
and morbidity with liver biopsies, this approach according
to current consensus guidelines is only justified if clinical
history, examination, laboratory results and abdominal
ultrasound [52] indicate sever NAFLD or NASH.
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In addition to its application for detecting NAFLD, the
index has been shown to be a useful predictor of arte-
riosclerosis development, independent of established clas-
sical risk factors in particular in those patients with a
score C 60 [53], and may also be an independent predictor
for the development of arterial fibrillation [54], diabetes
[55], cardiovascular and all-cause mortality [21, 24]. If
these results are directly transferable to patients with
hypopituitarism with their unique hormonal setting
demands however further evaluation.
A further limitation is the cross-sectional non-controlled
design of our study. Reasons for not using GHD replacement
therapy are various and may range from missing subjective
or objective benefit from treatment aswell as development of
side effects or a general refusal of daily injections. Further
prospective studies including a separate analysis of HC
replacement regimes are therefore needed to evaluation the
obviously complex role of GHD and HC in NAFLD among
patients with pituitary dysfunction. Despite these limita-
tions, we believe our data provide important implications for
a better understanding NAFLD in general and its manage-
ment of in patients with pituitary insufficiencies.
Conclusion
In summary we could show that while HC dosage affects
FLI as an estimate of NAFLD in patients with pituitary
adenomas the benefit of GH replacement still needs to be
determined. In contrast to reports in CD patients with
active disease, NAFLD in those biochemically controlled
was not significantly increased in comparison to NFAP
patients. Our study also contributes to the understanding of
the role of cortisol in the development of NAFLD. Further
studies should assess the diagnostic accuracy in compar-
ison to histological criteria and its prognostic implications
in this special patient population.
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